CeriBell (CBLL) CG MedTech, Diagnostics and Digital Health & Services Forum summary

Key business highlights

• Developed a novel, easy-to-use EEG monitoring system for acute care, enabling rapid setup and continuous monitoring, now active in 615 US hospitals, representing about 10% of the target market.

• Achieved $22.6 million in quarterly revenue, with a run rate of $90 million and 31% year-over-year growth in Q3, operating at 88% gross margins.

• Revenue model is highly predictable, with about 25% from SaaS subscriptions and 75% from disposable headbands, supporting consistent growth and confidence post-IPO.

• Expanded sales force from mid-30s to mid-50s territories post-IPO, with new hires expected to drive significant growth impact starting in 2026.

• Only 30% penetrated into active accounts, with a robust pipeline and focus on both deepening existing relationships and acquiring new accounts.

Product innovation and competitive positioning

• The system addresses acute care needs by enabling EEG setup in five minutes, overcoming delays and technician shortages associated with conventional EEG.

• Combines hardware (disposable headband, compact recorder) and software (Clarity seizure detection algorithm) for bedside alerts and actionable data.

• Holds a unique data asset with over 200,000 EEGs and extensive labeling, supporting a defensible AI algorithm and over 100 clinical publications.

• Differentiation is driven by both the algorithm and user-friendly form factor, with widespread adoption and proven clinical value.

Financial outlook and operational strategy

• Guidance for FY is $87–89 million, with seasonality in Q4 and Q1 due to higher ICU census; business model supports high projectability and conservative guidance.

• Gross margins guided to mid-80s, with ongoing mitigation of tariff impacts through supply chain diversification between China and Vietnam.

• Manufacturing flexibility allows for supply chain resilience, with a shift toward Vietnam to optimize costs.

• Committed to profitability without additional capital, balancing growth investments with high gross margins and operational flexibility.